Acadian Asset Management LLC has recently announced that it has increased stake in Dermata Therapeutics Inc (NASDAQ:DRMA) by 34.21%. After grabbing 75538.0 shares, the institutional investor is now in possession of 19253.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 2.37% having worth around $56276.0. Moreover, Geode Capital Management LLC increased its share by 12237.0 to have a control over 12237.0 shares. And Two Sigma Securities LLC raised its holdings to 11087.0 shares by acquiring 11087.0 shares or 0.35% of the stake.
Dermata Therapeutics Inc (DRMA) concluded trading on 01/04/24 at a closing price of $0.61, with 5.89 million shares of worth about $3.59 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -62.12% during that period and on Thursday the price saw a gain of about 1.70%. Currently the company’s common shares owned by public are about 3.19M shares, out of which, 2.79M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
The company recently came buying 0.0 shares which brought its stake up to 0.35% of the company’s outstanding shares.
Dermata Therapeutics Inc (NASDAQ: DRMA) started trading at $0.5825, below -$0.02 from concluding price of the previous day. However, the stock later moved at a day high price of 0.6200, or with a gain of 1.70%. Stock saw a price change of 5.16% in past 5 days and over the past one month there was a price change of -18.68%. Year-to-date (YTD), DRMA shares are showing a performance of -0.02% which decreased to -87.70% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.54 but also hit the highest price of $5.62 during that period. The average intraday trading volume for Dermata Therapeutics Inc shares is 229.99K. The stock is currently trading -7.79% below its 20-day simple moving average (SMA20), while that difference is down -10.10% for SMA50 and it goes to -52.01% lower than SMA200.
Acadian Asset Management LLC acquired 75538.0 shares of Dermata Therapeutics Inc having value of about $56276.0. Data submitted at the U.S SEC by Acadian Asset Management LLC revealed that the firm now holds 19253.0 shares in the company valued at close to $11744.33, or have control over 34.21% stake in the company. Dermata Therapeutics Inc (NASDAQ: DRMA) currently have 3.19M outstanding shares and institutions hold larger chunk of about 3.29% of that. Holding of mutual funds in the company is about 0.38% while other institutional holders and individual stake holders have control over 2.90% and — of the stake respectively.
The stock has a current market capitalization of $1.95M and its 3Y-monthly beta is at 0.85. It has posted earnings per share of -$5.61 in the same period. It has Quick Ratio of 7.99 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DRMA, volatility over the week remained 7.81% while standing at 8.94% over the month.
Analysts are in expectations that Dermata Therapeutics Inc (DRMA) stock would likely to be making an EPS of $Doma Holdings, Inc. in the current quarter, while forecast for next quarter EPS is $4.65 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $DMA which is $Global X Conscious Companies ET at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $DRMAW in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 69.68% while it is estimated to increase by 44.31% in next year.
Analysts at 1 brokerage firms have issued recommendations for the Dermata Therapeutics Inc (DRMA)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
